Fount of Information

TriLink BioTechnologies社 Thermostable RNA Vaccine Delivery Promises Enhanced Pandemic Response

このセミナーに関するご照会・お問合せはこちら
TriLink_logo.png

Manipulating_CD38_for_a_Novel_Immuno-Oncology_Therapy.png

Thermostable RNA Vaccine Delivery Promises Enhanced Pandemic Response

RNA-based vaccines offer several advantages over traditional ones, including faster production, simpler scale-up, and more rapid adaptability to new targets. These factors have proven critical in tackling the ongoing COVID-19 pandemic, allowing vaccines targeting SARS-CoV-2 to be developed in record time, while also enabling the rapid evolution of vaccination strategies as new strains of the virus emerge. Both Pfizer/BioNTech and Moderna received regulatory approval for their mRNA vaccine products within a year of the novel coronavirus first being sequenced, and many more RNA vaccines are currently in clinical trials...

Read_More_FOI.PNG

Your partner for mRNA vaccine development

The recent clinical success of mRNA vaccines against SARS-CoV-2 paves the way for future vaccine development. Whether you are in the discovery phase or nearing GMP manufacturing, TriLink offers a solution to fit your mRNA vaccine program:

·    Plasmid manufacturing for use as an IVT template

·    Custom mRNA synthesis from RUO through GMP grade

·    CleanCap® capping technology for non-replicating mRNA and self-amplifying mRNA

Learn more about how TriLink can support your vaccine development program.

 mRNA Vaccine Solutions.PNG
 Learn_More_FOI.PNG

Fount of Information は、新商品、新規取扱メーカーなどの情報をいち早く紹介するコンテンツです。情報発信のスピードを重視しているコンテンツのため、現時点で法規制や取り扱いを確認できていない商品、定価を設定できていない商品があります。ご要望やご照会を受けた商品について、法令整備や在庫の充実を図ります。